JUL 10, 2018 09:00 PM PDT

Risk Allele Variant SNP at 14q11.2 Linked to ALL

Acute Lymphoblastic Leukemia, or ALL, is a B-cell disorder that affects pediatric patients and is the most common childhood cancer diagnosed.  Patients with this diagnosis produce too many immature B-cells; a process driven by genetic mutations or predisposing factors.  It is well established that around 60% of ALL diagnoses are found to have the presence of a translocation between chromosomes 12 and 21, which produces the commonly characterized chimeric ETV6-RUNX1 protein. Another genetic change occurs in a smaller percentage of patients that involves a translocation of chromosomes 5 and 14, which affect genes in the immunoglobulin heavy chain and interleukin-3. 

A new study just published July 6, 2018 in the journal Leukemia examined ALL and genetic risk factors, specifically locations of genetic variants and their potential association with the disease.  The authors of the study utilized genome-wide association studies (GWAS) to identify 11 specific loci linked to ALL.  The loci are all located in proximity to B-cell development genes.  The authors of the study identified an at-risk locus at 14q11.2, which encodes a gene called CCAAT enhancer-binding protein epsilon (CEBPE).  The CEBPE protein produced regulates a distinct pattern of nucleotides (CCAAT) that act as a promoter region for other genes. When the protein is upregulated, as in ALL, the promoter region is turned on and continues to promote early B-cell proliferation which becomes uncontrolled.  There is a specific single nucleotide polymorphism identified that enhances that CEBPE promoter region.  The variant, rs2239630, has an adenine inserted where a guanine should be.  This 14q11.2 SNP risk allele affects granulocyte differentiation and myelopoetic defects.  Ultimately, CEPBE differential expression may provide a basis for the 14q11.2 risk connected with ALL. 

Scientific advances is sequencing genes could provide an opportunity to better predict and monitor potential patients who carry the variant allele associated in this case.  Early diagnosis and treatment is key for children with ALL.

Sources: Leukemia, National Cancer Institute, NCBI dbSNP, Leukemia & Lymphoma Society, Hematology/Oncology Clinics of North America,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
OCT 30, 2018
Drug Discovery
OCT 30, 2018
Re-sensitizing Drug-resistant Human Tumor Cells
Understanding how cancer cells avoid death despite their DNA being damaged will create new strategies to enhance cancer cell killing through chemotherapy t...
DEC 11, 2018
Cancer
DEC 11, 2018
FDA approves two new drugs for cancers with specific genetic mutations
Last month the FDA approved two new drugs for cancer, both drugs target cancers with specific genetic mutations which made geneticists and oncologists optimistic on the future of cancer thera...
DEC 19, 2018
Immunology
DEC 19, 2018
Breast Cancer - Immunotherapy's Nemesis
Researchers find that breast cancer can evade immunotherapy...
JAN 16, 2019
Cell & Molecular Biology
JAN 16, 2019
Molecule Can Reduce the Growth & Spread of Breast Cancer
A protein called Nischarin can help stop breast cancer from growing and metastasizing....
JAN 24, 2019
Microbiology
JAN 24, 2019
WHO Names the Top Threats to Human Health in 2019
Unsurprisingly, microbial pathogens and related issues, like a growing hesitancy surrounding the use of vaccines, make up a large portion of that list....
FEB 12, 2019
Cancer
FEB 12, 2019
How Long Has Cancer Been Around?
Cancer is on everybody's mind these days. Many pharmaceutical companies are devoted solely to finding new cancer treatments. In 2016, President Obama c...
Loading Comments...